Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Reduce My Belly Fat?
The honest map across 6 belly fat scenarios — fat type, what's been studied, and where validated obesity medicine still rules.
WHICH BELLY FAT CONTEXT?
Belly Fat Context
Animal Studies
Human Trials
Subcutaneous belly fat (under-skin)
general weight loss context
Visceral abdominal fat (around organs)
cardiometabolic-risk fat
HIV-associated lipodystrophy
FDA-approved Tesamorelin indication
Obesity with BMI 30+ or BMI 27+ with comorbidities
FDA-approved GLP-1 RA indications
Type 2 diabetes with abdominal obesity
T2DM + obesity context
Stress-related cortisol-driven belly fat
cortisol-mediated central adiposity
Post-pregnancy abdominal weight retention
postpartum body composition
Adjunct after lifestyle and validated therapy optimized
validated foundation first
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Belly fat reduction has well-characterized validated approaches. Foundations include accurate body composition assessment, screening for comorbid metabolic conditions, and individualized therapy matching per AHA, ACC, and obesity medicine guidelines. Validated approaches include FDA-approved GLP-1 RAs (Wegovy, Saxenda) and dual agonists (Zepbound). Additional foundations include caloric deficit, resistance training, adequate sleep, stress management, and bariatric surgery for severe obesity.
Tesamorelin anchors the visceral fat-specific peptide literature on this page. The compound holds FDA approval (Egrifta) for HIV-associated lipodystrophy with central abdominal fat accumulation. Phase 3 trials report substantial visceral adipose tissue reduction.
Semaglutide is FDA-approved (Wegovy) for chronic weight management with substantial weight loss including belly fat in Phase 3 STEP trials. The compound is a GLP-1 receptor agonist with weekly subcutaneous administration.
Tirzepatide is FDA-approved (Zepbound) for chronic weight management with substantial weight loss in SURMOUNT trials. The compound is a dual GIP/GLP-1 receptor agonist with effect sizes exceeding semaglutide in head-to-head comparisons.
Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist in late Phase 2 / Phase 3 development. The Phase 2 trial reported 24.2 percent body weight loss at 48 weeks including MRI-quantified belly fat reduction. Not yet FDA-approved.
AOD-9604 is community-discussed for fat loss with thin direct human evidence. The compound is a synthetic fragment of human growth hormone. Phase 2 trials produced negative weight loss results.
The honest framing: three peptides hold FDA approvals with substantial Phase 3 belly fat reduction evidence. Retatrutide Phase 2 evidence is promising but not yet FDA-approved. AOD-9604 is research-grade with negative trial history. For broader context, see the Peptides for Visceral Fat and Peptides for Cardiovascular Health.
Tesamorelin vs GLP-1 RAs for visceral abdominal fat
FDA-approved options with different mechanisms and approval scopes
Tesamorelin (Egrifta) holds FDA approval specifically for HIV-associated lipodystrophy with central abdominal fat accumulation. Phase 3 trials report 15-20 percent visceral adipose tissue reduction over 26 weeks. The mechanism is GHRH analog stimulation of endogenous GH with effects on visceral fat lipolysis. The approval is narrow and population-specific.
GLP-1 receptor agonists (Semaglutide as Wegovy, Tirzepatide as Zepbound) hold FDA approval for chronic weight management without HIV-specific indication. Phase 3 STEP and SURMOUNT trials report substantial body weight loss including proportional reductions across body compartments including belly fat. Mechanism is appetite suppression and metabolic effects rather than direct visceral fat targeting.
PSI's reading: for HIV-associated lipodystrophy, Tesamorelin is the validated FDA-approved option targeting visceral fat directly. For broader belly fat reduction in obesity, FDA-approved GLP-1 RAs and dual agonists hold validated positioning with substantial weight loss including belly fat as part of overall reduction. Obesity medicine, endocrinology, or HIV care specialty guidance ensures appropriate matching.
Semaglutide vs Tirzepatide for belly fat
Comparing the two FDA-approved chronic weight management options
Semaglutide (Wegovy) holds FDA approval for chronic weight management based on Phase 3 STEP trials reporting approximately 15 percent body weight loss over 68 weeks. The compound is a GLP-1 receptor agonist with once-weekly subcutaneous administration.
Tirzepatide (Zepbound) holds FDA approval for chronic weight management based on Phase 3 SURMOUNT trials reporting approximately 20-22 percent body weight loss over 72 weeks. The SURMOUNT-5 head-to-head trial demonstrated greater weight loss with tirzepatide than semaglutide. Mechanism is dual GIP and GLP-1 receptor agonism. Once-weekly subcutaneous administration.
PSI's reading: both peptides hold validated FDA-approved chronic weight management indications with substantial Phase 3 evidence. Tirzepatide demonstrates larger effect sizes in head-to-head comparison. Patient selection considers tolerance, contraindications, insurance coverage, and individualized therapy matching under obesity medicine, endocrinology, or primary care guidance.
Retatrutide vs Tirzepatide for belly fat (investigational vs FDA-approved)
Phase 2 effect sizes vs Phase 3 validated approval
Tirzepatide (Zepbound) holds FDA approval based on Phase 3 SURMOUNT-1 with 22.5 percent body weight loss over 72 weeks. SURMOUNT-5 head-to-head demonstrated greater weight loss than semaglutide. The compound is the largest-effect-size FDA-approved chronic weight management option in 2026.
Retatrutide is investigational with Phase 2 trial demonstrating 24.2 percent body weight loss at 48 weeks at the 12mg dose. The triple receptor mechanism (GIP/GLP-1/glucagon) may exceed dual receptor effect sizes pending Phase 3 readout. Phase 3 TRIUMPH program is enrolling. Cross-trial comparison suggests Retatrutide may exceed Tirzepatide effect sizes but head-to-head Phase 3 data is not yet available. Not FDA-approved as of 2026.
PSI's reading: Tirzepatide is the validated FDA-approved largest-effect-size chronic weight management option. Retatrutide Phase 2 evidence is promising for next-generation effect sizes pending Phase 3 readout. Patients pursuing belly fat reduction in 2026 should work with FDA-approved options under obesity medicine guidance. TRIUMPH trial enrollment may be appropriate for some patients pursuing investigational therapy.
Peptides vs lifestyle and validated foundations for belly fat
Where peptides fit alongside the broader belly fat reduction toolkit
Lifestyle interventions for belly fat reduction have substantial evidence base. Caloric deficit through dietary intervention drives overall weight loss including belly fat. Resistance training preserves lean mass during weight loss and supports body composition. Aerobic exercise improves cardiometabolic health and supports weight loss. Adequate sleep prevents cortisol-driven central adiposity. Stress management reduces cortisol-mediated belly fat accumulation. Limited alcohol consumption supports weight management. Mediterranean and DASH diet patterns have evidence base.
Bariatric surgery (gastric sleeve, gastric bypass, others) has substantial Phase 3 and observational evidence for severe obesity (BMI 40+ or BMI 35+ with comorbidities) with effect sizes substantially larger than pharmacotherapy. Validated for appropriate candidates under bariatric surgery specialty guidance.
PSI's reading: lifestyle foundations are essential alongside any pharmacotherapy or surgical intervention. FDA-approved GLP-1 RAs and Tesamorelin produce meaningful belly fat reduction in their approved populations as additive to (not substitutes for) lifestyle interventions. Bariatric surgery applies to severe obesity. Comprehensive belly fat care integrates lifestyle, pharmacotherapy, and surgical options as indicated.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 5 peptides discussed for belly fat reduction, three carry FDA approvals with substantial Phase 3 evidence. Tesamorelin holds FDA approval (Egrifta) specifically for HIV-associated visceral fat reduction. Semaglutide holds FDA approval (Wegovy) for chronic weight management. Tirzepatide holds FDA approval (Zepbound) for chronic weight management with substantial weight loss in SURMOUNT trials. Retatrutide is in Phase 2/3 development with reported 24.2 percent body weight loss in Phase 2. AOD-9604 is community-discussed with thin direct human evidence. Validated obesity medicine including GLP-1 RAs, lifestyle interventions, and bariatric surgery dominates evidence-graded belly fat care.
Tirzepatide
FDA-approved Zepbound for chronic weight management with SURMOUNT 20-22 percent body weight loss. Effect sizes exceed semaglutide in head-to-head.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management including belly fat FDA-approved Zepbound indication | 8 Dual GIP/GLP-1 receptor agonist weight loss effects with body composition changes. | 6 Phase 3 SURMOUNT trials supporting FDA approval; 20-22 percent body weight loss. Jastreboff 2022 |
Head-to-head vs Semaglutide comparative effect size context | 4 Comparative effect sizes in animal models. | 2 SURMOUNT-5 head-to-head trial supporting greater weight loss vs Semaglutide. Aronne 2024 |
Semaglutide
FDA-approved Wegovy for chronic weight management with STEP 15 percent body weight loss. Substantial Phase 3 evidence.
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management including belly fat FDA-approved Wegovy indication | 8 GLP-1 receptor agonist weight loss effects with body composition changes in animal models. | 6 Phase 3 STEP trials supporting FDA approval; 15 percent body weight loss over 68 weeks. Wilding 2021 |
T2DM weight management FDA-approved Ozempic indication | 6 Glucose regulation + weight loss in diabetic models. | 6 Phase 3 SUSTAIN trials supporting Ozempic approval. |
Tesamorelin
FDA-approved Egrifta for HIV-associated lipodystrophy with Phase 3 visceral fat reduction by 15-20 percent over 26 weeks.
| Context | Animal Studies | Human Trials |
|---|---|---|
HIV-associated visceral fat reduction FDA-approved Egrifta indication | 6 GHRH analog effects on body composition with visceral fat targeting in animal models. | 6 Phase 3 trials supporting FDA approval; 15-20 percent visceral fat reduction over 26 weeks. Falutz 2007 |
Off-label non-HIV visceral fat off-label use context | 4 Visceral fat reduction in non-HIV animal models. | 2 Limited off-label use studies; absent Phase 3 outcome trials in non-HIV populations. |
Retatrutide
Investigational triple agonist with Phase 2 24.2 percent body weight loss including MRI-quantified belly fat reduction. Phase 3 TRIUMPH enrolling.
| Context | Animal Studies | Human Trials |
|---|---|---|
Phase 2 weight loss with belly fat reduction investigational triple agonist | 6 Triple receptor agonist weight loss effects with enhanced energy expenditure in animal models. | 4 Phase 2 obesity trial with 24.2 percent body weight loss including MRI-quantified belly fat reduction at 48 weeks. Jastreboff 2023 |
Phase 2 T2DM glucose and weight effects T2DM development context | 4 Glucose regulation and weight loss in diabetic models. | 2 Phase 2 T2DM trial supporting Phase 3 TRIUMPH enrollment. Rosenstock 2023 |
AOD-9604
Phase 2 trials produced negative weight loss results. Pharmaceutical development discontinued. Community use despite negative evidence.
| Context | Animal Studies | Human Trials |
|---|---|---|
Belly fat reduction (Phase 2 negative) primary indication on this page | 8 Lipolytic effects in obese animal models. Heffernan 2001 | 4 Phase 2 trials produced negative weight loss results vs placebo; pharmaceutical development discontinued. |
What's Marketed vs What's Studied
6 common claims, corrected.
“Peptides specifically melt belly fat without overall weight loss.”
FDA-approved GLP-1 RAs and dual agonists produce overall weight loss with proportional reductions across body compartments including belly fat. Effect sizes are not specifically targeted to belly fat over other compartments. Tesamorelin within HIV-associated lipodystrophy approval has more visceral-fat-targeted effects but is narrow population. Spot-fat-reduction marketing overstates the evidence base.
“Retatrutide is the new go-to for belly fat.”
Retatrutide Phase 2 evidence is promising with 24.2 percent body weight loss including MRI-quantified belly fat reduction. The compound is investigational with Phase 3 TRIUMPH program enrolling. Not yet FDA-approved as of 2026. Compounded availability faces FDA enforcement action. Validated FDA-approved options including Tirzepatide, Semaglutide, and Tesamorelin (HIV indication) hold current evidence-graded belly fat positioning.
“AOD-9604 is a proven fat loss peptide.”
AOD-9604 had Phase 2b trials in obesity produce negative weight loss results compared to placebo. Pharmaceutical development was discontinued for obesity indication. Community use persists despite negative trial evidence and is not validated practice. FDA-approved GLP-1 RAs and dual agonists have substantial Phase 3 weight loss evidence.
“Tesamorelin works for general belly fat in non-HIV patients.”
Tesamorelin (Egrifta) holds FDA approval specifically for HIV-associated lipodystrophy. Phase 3 evidence is in HIV populations. Off-label use in non-HIV contexts lacks Phase 3 outcome evidence in those populations. Insurance coverage typically does not extend to off-label use. FDA-approved GLP-1 RAs and dual agonists have validated chronic weight management indications.
“GLP-1 RAs are a magic shortcut without lifestyle changes.”
FDA-approved GLP-1 RAs produce substantial weight loss but are additive to (not substitutes for) lifestyle interventions. Caloric deficit, resistance training to preserve lean mass during weight loss, adequate sleep, and stress management remain foundational. Discontinuation typically results in weight regain. Comprehensive obesity care integrates lifestyle and pharmacotherapy.
“I can lose belly fat without seeing a doctor using peptides.”
Belly fat reduction in clinical practice requires comprehensive metabolic assessment, screening for comorbid conditions (T2DM, hypertension, dyslipidemia, sleep apnea), and individualized therapy matching. Self-treatment with research-grade peptides bypasses essential clinical evaluation. Always work with obesity medicine, endocrinology, primary care, or HIV care specialty.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive metabolic assessment.
BMI, waist circumference, lipid panel, fasting glucose or HbA1c, blood pressure, sleep apnea screening, and screening for T2DM, hypertension, dyslipidemia, hypothyroidism, and PCOS guide therapy matching.
Match FDA-approved indications to your situation.
Wegovy and Zepbound for chronic weight management (BMI 30+ or 27+ with comorbidities). Tesamorelin for HIV-associated lipodystrophy. Mounjaro and Ozempic for T2DM. Saxenda for chronic weight management. Specialty guidance ensures appropriate matching.
Optimize lifestyle foundations alongside any therapy.
Caloric deficit, resistance training to preserve lean mass during weight loss, aerobic exercise, adequate sleep, stress management, and limited alcohol form the validated foundation.
Consider Phase 3 TRIUMPH trial enrollment for investigational Retatrutide.
Trial enrollment provides monitored access within validated clinical research framework. Compounded Retatrutide outside trials faces FDA enforcement action and lacks safety monitoring.
Review GLP-1 RA contraindications carefully.
Personal or family history of medullary thyroid carcinoma and MEN 2 syndrome are absolute contraindications. Pregnancy and severe gastrointestinal disease require careful consideration.
Consider bariatric surgery evaluation for severe obesity.
Bariatric surgery applies to BMI 40+ or BMI 35+ with comorbidities with effect sizes substantially larger than pharmacotherapy. Bariatric surgery specialty consultation guides candidacy assessment.
Avoid compounds with negative trial evidence.
AOD-9604 had Phase 2 negative weight loss trials. Community use persists despite negative evidence and is not validated practice. FDA-approved options have substantial Phase 3 evidence.
The regulatory landscape for belly fat reduction is dynamic. Phase 3 TRIUMPH (Retatrutide) program is enrolling with potential FDA approval pending readout. Tirzepatide cardiovascular outcome trial (SURMOUNT-MMO) is in progress. New GLP-1 and dual agonist compounds continue Phase 3 development. Compounded GLP-1 RAs face regulatory scrutiny following FDA safety communications. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any peptides FDA-approved for belly fat reduction?
Yes, three peptides hold FDA approvals with belly fat reduction implications. Tesamorelin (Egrifta) is FDA-approved specifically for HIV-associated lipodystrophy with Phase 3 visceral fat reduction evidence. Semaglutide (Wegovy) is FDA-approved for chronic weight management with substantial weight loss including belly fat in STEP trials. Tirzepatide (Zepbound) is FDA-approved for chronic weight management with even larger weight loss in SURMOUNT trials. Retatrutide is investigational with Phase 3 TRIUMPH enrolling. AOD-9604 had Phase 2 negative weight loss trials.
Should I work with an obesity medicine specialist for belly fat?
Yes for moderate to severe obesity or when initial primary care management is insufficient. Obesity medicine specialty involvement ensures comprehensive metabolic assessment, screening for comorbid conditions (T2DM, hypertension, dyslipidemia, sleep apnea), and individualized therapy matching. Endocrinology specialty also handles obesity care. Primary care can manage many initial cases. HIV care specialty handles Tesamorelin for FDA-approved indication.
What is the strongest validated belly fat treatment?
Multiple validated approaches have substantial evidence. Tirzepatide (Zepbound) produces approximately 20-22 percent body weight loss in SURMOUNT trials. Semaglutide (Wegovy) produces approximately 15 percent body weight loss in STEP trials. Tesamorelin produces 15-20 percent visceral fat reduction in HIV-associated lipodystrophy. Bariatric surgery produces larger effect sizes for severe obesity. Lifestyle interventions including caloric deficit, resistance training, and sleep optimization form the foundation alongside pharmacotherapy.
Does Tirzepatide really work better than Semaglutide?
Yes, in head-to-head comparison. The SURMOUNT-5 trial directly compared tirzepatide and semaglutide in adults with obesity and demonstrated greater weight loss with tirzepatide. Phase 3 SURMOUNT-1 alone showed up to 22.5 percent body weight loss with tirzepatide vs 14.9 percent with semaglutide in STEP-1 (different trials but comparable populations). Both are validated FDA-approved options; patient selection considers tolerance, insurance coverage, and individualized factors.
What about Retatrutide for belly fat?
Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) in late Phase 2 / Phase 3 development. The Phase 2 trial reported 24.2 percent body weight loss at 48 weeks at the 12mg dose with MRI-quantified belly fat reduction. The triple receptor mechanism with glucagon component theoretically targets belly fat through enhanced energy expenditure plus appetite suppression. Phase 3 TRIUMPH program is enrolling. Not FDA-approved as of 2026. Compounded availability faces FDA enforcement action.
Should I try Retatrutide before it's FDA-approved?
Patients pursuing investigational Retatrutide therapy should consider Phase 3 TRIUMPH trial enrollment for monitored access within validated clinical research framework. Compounded Retatrutide outside clinical trials faces FDA enforcement action and lacks the safety monitoring of formal trial enrollment. Validated FDA-approved options including Tirzepatide, Semaglutide, and Tesamorelin (HIV indication) hold current evidence-graded belly fat positioning. Obesity medicine or endocrinology specialty guidance helps individualized decision-making.
Can GLP-1 RAs target belly fat specifically?
FDA-approved GLP-1 RAs and dual agonists produce overall weight loss with proportional reductions across body compartments including belly fat. Effect sizes are not specifically targeted to belly fat over other compartments. Tesamorelin within HIV-associated lipodystrophy approval has more direct visceral fat targeting through GHRH mechanism. Spot-fat-reduction marketing overstates the evidence.
What about Tesamorelin for non-HIV belly fat?
Tesamorelin (Egrifta) holds FDA approval specifically for HIV-associated lipodystrophy. Phase 3 evidence is in HIV populations with 15-20 percent visceral fat reduction. Off-label use in non-HIV contexts exists in integrative medicine and obesity medicine but lacks Phase 3 outcome trial evidence in those populations. Insurance coverage typically does not extend to off-label use given narrow FDA approval.
Does AOD-9604 actually reduce belly fat?
No based on Phase 2 trial evidence. Phase 2b trials of AOD-9604 in obesity produced negative weight loss results compared to placebo over 12 weeks. Pharmaceutical development was discontinued for obesity indication. Community use of AOD-9604 persists despite negative trial evidence but is not validated practice. FDA-approved GLP-1 RAs and dual agonists have substantial Phase 3 evidence.
What lifestyle changes have strongest belly fat evidence?
Multiple lifestyle interventions have substantial validated evidence. Caloric deficit through dietary intervention drives overall weight loss including belly fat. Resistance training preserves lean mass during weight loss. Aerobic exercise improves cardiometabolic health. Adequate sleep prevents cortisol-driven central adiposity. Stress management reduces cortisol-mediated belly fat. Limited alcohol consumption supports weight management. Mediterranean and DASH diet patterns have evidence base.
Can I expect to keep weight off after stopping GLP-1 RAs?
Discontinuation of GLP-1 RAs typically results in weight regain in published Phase 3 extension data. The STEP-4 trial demonstrated weight regain after semaglutide discontinuation. Long-term sustained therapy is the typical clinical pattern for chronic weight management. Some patients transition to validated maintenance approaches. Obesity medicine specialty guidance helps plan long-term management.
Should I screen for sleep apnea and other conditions?
Yes. Sleep apnea is highly underdiagnosed in obesity and contributes to belly fat through cortisol and metabolic disruption. STOP-BANG screening and home sleep apnea testing or polysomnography identify cases. CPAP therapy substantially improves outcomes. Other conditions to screen include T2DM, hypertension, dyslipidemia, hypothyroidism, and PCOS in women. Comprehensive metabolic assessment guides validated therapy matching.
Are GLP-1 RAs safer than bariatric surgery?
The comparison is not equivalent. Both have substantial validated evidence with characterized risk-benefit profiles. GLP-1 RAs have characterized side effects (gastrointestinal symptoms, rare pancreatitis, contraindications in MEN 2 syndrome). Bariatric surgery has surgical and long-term nutritional risks but produces larger sustained effect sizes for severe obesity. Obesity medicine and bariatric surgery specialty guidance helps individualized therapy matching considering BMI, comorbidities, and patient preferences.
What questions should I ask a doctor about peptides for belly fat?
Ask: (1) What is my comprehensive metabolic assessment and BMI? (2) For my situation, what FDA-approved options apply (Wegovy, Zepbound, Saxenda for obesity; Mounjaro and Ozempic for T2DM; Tesamorelin for HIV-associated lipodystrophy)? (3) Have I optimized lifestyle foundations including caloric deficit, resistance training, and sleep? (4) Should I consider bariatric surgery evaluation if BMI 35-40+? (5) Is Phase 3 TRIUMPH (Retatrutide) trial enrollment appropriate for my situation? (6) For research-grade peptides like AOD-9604, what evidence supports use given negative Phase 2 trials? (7) How do GLP-1 RA contraindications apply to my situation?
Can peptides help with stress-related belly fat?
Stress-driven cortisol contributes to central adiposity. Validated approaches include stress management (mindfulness, CBT, exercise), adequate sleep, and addressing underlying stressors. FDA-approved GLP-1 RAs and dual agonists produce weight loss including belly fat in eligible candidates. Tesamorelin targets visceral fat in HIV-associated lipodystrophy. Cortisol-specific peptide interventions are not FDA-approved and have thin evidence base.
Are these peptides legal in the United States?
Tesamorelin (Egrifta), Semaglutide (Wegovy, Ozempic, Rybelsus), and Tirzepatide (Zepbound, Mounjaro) are FDA-approved with established commercial products available by prescription. Retatrutide is investigational; access is through Phase 3 TRIUMPH trial enrollment. AOD-9604 is research-only with limited compounded availability through 503A pharmacies for off-label use despite negative Phase 2 trial evidence. The FDA has issued safety communications about various compounded peptides. Always work with a licensed prescriber within validated medical framework.
Should I expect dramatic belly fat reduction from peptides?
Realistic expectations align with the evidence base. FDA-approved GLP-1 RAs and dual agonists produce substantial weight loss in their approved populations (15 percent for semaglutide, 20-22 percent for tirzepatide over 68-72 weeks). Tesamorelin produces 15-20 percent visceral fat reduction in HIV-associated lipodystrophy. Retatrutide Phase 2 produced 24.2 percent body weight loss. AOD-9604 had negative Phase 2 weight loss trials. Effect sizes are meaningful but require sustained therapy and lifestyle integration. Discontinuation typically results in weight regain.
What are the side effects of belly fat peptides?
Semaglutide and Tirzepatide GLP-1 RA and dual agonist side effects include nausea, vomiting, diarrhea, and constipation (typically dose-dependent). Rare side effects include pancreatitis. Personal or family history of medullary thyroid carcinoma and MEN 2 syndrome are absolute contraindications. Tesamorelin side effects include injection site reactions, joint pain, and IGF-1 elevations requiring monitoring. Retatrutide Phase 2 side effects mirror dual agonist class with gastrointestinal symptoms. AOD-9604 has limited human safety data outside negative Phase 2 trials. All peptide use should occur under specialty guidance with appropriate monitoring.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.